PROLACTIN AND THE BREAST: NEW DATA OF RANDOMIZED TRIALS


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To make a systemic analysis of the data available in the current literature on the synthesis of prolactin, its mechanism of action and its effect on the risk of breast cancer. Subject and methods. The review includes the data of foreign and Russia articles that were found in Pubmed on th is topic and published manly in the past 10 years. Results. The prolactin level increase up to more than 8.3 ng/ml less than 10 years before the identification of neoplasias was shown to correlate with the development of invasive estrogen-receptor-positive (ER+) breast cancer. Conclusion. There is a need for further studies to assess the risk of breast cancer in the presence of higher prolactin concentrations. Acting on prolactin and its signaling pathways may be considered as a promising way to treat and possibly to prevent breast cancer.

Full Text

Restricted Access

About the authors

Natalia Mikhaylovna Podzolkova

Russian Medical Academy of Postgraduate Education, Ministry of Health of the Russian Federation

Dr.med.sc., professor, academician of the Academy of Natural Sciences, Head of the Department of Obstetrics and Gynecology Moscow 125993, Barrikadnaya str. 2/1, Russia

L. V Sumyatina

Russian Medical Academy of Postgraduate Education, Ministry of Health of the Russian Federation

Email: Sumyatin@yandex.ru
PhD, department of obstetrics and gynecology Moscow 125993, Barrikadnaya str. 2/1, Russia

Yu. A Mokhova

Russian Medical Academy of Postgraduate Education, Ministry of Health of the Russian Federation

Ph.D., World Federation of Surgical Oncology Societies Moscow 125993, Barrikadnaya str. 2/1, Russia

References

  1. Андреева Е.Н., Хамошина М.Б., Руднева О.Д. Пролактин и молочные железы: норма и патология. Гинекология. 2012; 14(1): 12-6. [
  2. Радзинский В.Е., ред. Молочные железы и гинекологические болезни. М.: StatusPraesens; 2010. 304с.
  3. Кэттайл В.М., Арки Р.А. Патофизиология эндокринной системы. СПб.: Невский Диалект, М.: БИНОМ; 2001. 336с.
  4. Gregerson K.A. Mechanism of dopamine action on the lactotrophs. Boston: Kluwer; 2001: 45-61.
  5. Потин В.В., Касумова А.Р., Рулев В.В., Тарасова М.А., Ткаченко Н.Н. Гиперпролактинемическая недостаточность яичников. Пособие для врачей. Айламазян Э.К., ред. СПб.: Н-Л; 2009. 24с.
  6. Калинченко С.Ю. Мифы и правда о гиперпролактинемии. Избранные лекции. М.: Практическая медицина; 2013. 108с.
  7. Подзолкова Н.М., Глазкова О.Л. Симптом. Синдром. Диагноз. Дифференциальная диагностика в гинекологии. 3-е изд. М.: ГЭОТАР-Медиа; 2014. 736с.
  8. Романцова Т.И., Мельниченко Г.А., Черноголов В.А. Проблемы диагностики гиперпролактинемических состояний. Гинекология. 1999; 1(2): 2-8.
  9. Ефремов Е.А., Гусакова Д.А., Мельник Я.И. Эректильная дисфункция у пациентов с гиперпролактинемией. Экспериментальная и клиническая урология. 2012; 1: 28-31
  10. Das D., Talukdar U., Chisty S.J.S., Das M.K., Das S. Serum prolactin level in patients taking olanzapine. Open J. Psychiatry Allied Sci. 2015; 6(1): 50-8.
  11. Тумилович Л.Г., Геворкян М.А. Справочник гинеколога- эндокринолога. 4-е изд. М.: Практическая медицина; 2015. 206с.
  12. McHale K., Tomaszewski J.E., Puthiyaveettil R., Livolsi V.A., Clevenger C.V. Altered expression of prolactin receptor-associated signaling proteins in human breast carcinoma. Mod. Pathol. 2008; 21(5): 565-71.
  13. Хамошина М.Б., Паренкова И.А. Не игнорировать мастопатию - не допускать рака. Информационное письмо. Радзинский В.Е., Рожкова Н.И., ред. М.: StatusPraesens; 2015. 24с.
  14. Кит О.И., Франциянц Е.М., Бандовкина В.А., Шатова Ю.С., Комарова Е.Ф., Верескунова М.И., Кучкина Л.П. Уровень половых гормонов и пролактина в ткани злокачественных опухолей молочной железы у больных разного возраста. Фундаментальные исследования. 2013; 7: 560-4
  15. Bernichtein S., Touraine P., Goffin V. New concepts in prolactin biology. J. Endocrinol. 2010; 206(1): 1-11.
  16. Berinder K., Akre O., Granath F., Hulting A-L. Cancer risk in hyperprolactinemia patients: a population-based cohort study. Eur. J. Endocrinol. 2011; 165(2): 209-15.
  17. Arendt L.M., Schuler L.A. Transgenic models to study actions of prolactin in mammary neoplasia. J. Mammary Gland Biol. Neoplasia. 2008; 13(1): 29-40.
  18. O’Leary K.A., Shea M.P., Schuler L.A. Modeling prolactin actions in breast cancer in vivo: insights from the NRL-PRL mouse. Adv. Exp. Med. Biol. 2015; 846: 201-20.
  19. Tworoger S.S., Hankinson S.E. Prolactin and breast cancer etiology: an epidemiologic perspective. J. Mammary Gland Biol. Neoplasia. 2008; 13(1): 41-53.
  20. Barcus C.E., Keely P.J., Eliceiri K.W., Schuler L.A. Stiff collagen matrices increase tumorigenic prolactin signaling in breast cancer cells. J. Biol. Chem. 2013; 288(18): 12722-32.
  21. Naderi A. Prolactin-induced protein in breast cancer. Adv. Exp. Med. Biol. 2015; 846: 189-200.
  22. Damiano J.S., Wasserman E. Molecular pathways: blockade of the PRLR signaling pathway as a novel antihormonal approach for the treatment of breast and prostate cancer. Clin. Cancer Res. 2013; 19(7): 1644-50.
  23. Manjer J., Johansson R., Berglund G., Janzon L., Kaaks R., Agren A. et al. Postmenopausal breast cancer risk in relation to sex steroid hormones, prolactin and SHBG (Sweden). Cancer Causes Control. 2003; 14(7): 599-607.
  24. Tworoger S.S., Eliassen A.H., Sluss P., Hankinson S.E. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J. Clin. Oncol. 2007; 25(12): 1482-8.
  25. Helzlsouer K.J., Alberg A.J., Bush T.L., Longcope C., Gordon G.B., Comstock G.W. A prospective study of endogenous hormones and breast cancer. Cancer Detect. Prev. 1994; 18(2): 79-85.
  26. Kabuto M., Akiba S., Stevens R.G., Neriishi K., Land C.E. A prospective study of estradiol and breast cancer in Japanese women. Cancer Epidemiol. Biomarkers Prev. 2000; 9(6): 575-9.
  27. Wang D.Y., De Stavola B.L., Bulbrook R.D., Allen D.S., Kwa H.G., Fentiman I.S. et al. Relationship of blood prolactin levels and the risk of subsequent breast cancer. Int. J. Epidemiol. 1992; 21(2): 214-21.
  28. Tworoger S.S., Eliassen A.H., Zhang X., Qian J., Sluss P.M., Rosner B.A., Hankinson S.E. A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development. Cancer Res. 2013; 73(15): 4810-9.
  29. Tikk K., Sookthai D., Johnson T., Rinaldi S., Romieu I., Tjonneland A. et al. Circulating prolactin and breast cancer risk among pre- and postmenopausal women in the EPIC cohort. Ann. Oncol. 2014; 25(7): 1422-8.
  30. Surazynski A., Miltyk W., Wolczynski S., Palka J. The effect of prolactin and estrogen cross-talk on prolidase- dependent signaling in MCF-7 cells. Neoplasma. 2013; 60(4): 355-63.
  31. Thomin A., Friszer S., Fajac A., Daraï É., Chabbert-Buffet N. Hormonal prevention of breast cancer. Ann. Endocrinol. (Paris). 2014; 75(3): 148-55.
  32. Clevenger C.V., Zheng J., Jablonski E.M., Galbaugh T.L., Fang F. From bench to bedside: future potential for the translation of prolactin inhibitors as breast cancer therapeutics. J. Mammary Gland Biol. Neoplasia. 2008; 13(1): 147-56.
  33. Damiano J.S., Rendahl K.G., Karim C., Embry M.G., Ghoddusi M., Holash J. et al. Neutralization of prolactin receptor function by monoclonal antibody LFA102, a novel potential therapeutic for the treatment of breast cancer. Mol. Cancer Ther. 2013; 12(3): 295-305.
  34. Goffin V., Touraine P. The prolactin receptor as a therapeutic target in human diseases: browsing new potential indications. Expert Opin. Ther. Targets. 2015; 19(9): 1229-44.
  35. Сметник В.П., Бутарева Л.Б. Опыт применения фитопрепарата «Циклодинон» («Агнукастон») у пациенток с недостаточностью функции желтого тела и гиперпролактинемией. Проблемы репродукции. 2005; 11(5): 50-4
  36. Уварова Е.В., Болдырева Н.В. Возможности негормональной коррекции уровня пролактина на фоне гормональной контрацепции у сексуально активных молодых. Русский медицинский журнал. 2007; 15(1): 1-6
  37. Halaska M., Beles P., Gorkow C., Sieder C. Treatment of cyclical mastalgia with a soluton containing a Vitex agnus castus extract: results of a placebo-controlled double-blind Study. Breast. 1999; 8(4): 175-81.
  38. Wuttke W., Splitt G., Gorkow C., Sieder C. Treatment of cyclical mastalgia with a medicinal product containing Agnus Castus. Results of a randomized, placebo-controlled, double blind study. Geburtsh. u. Frauenheilk. 1997; 57: 569-74.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies